Peer-influenced content. Sources you trust. No registration required. This is HCN.

The New England Journal of MedicineAdjuvant Pembrolizumab after Nephrectomy in Renal Cell Carcinoma

Pembrolizumab was randomly given to 496 patients, while a placebo was given to 498. The estimated percentage of patients still alive at 24 months was 96.6% in the pembrolizumab group and 93.5% in the placebo group. Pembrolizumab therapy was associated with a significantly longer disease-free survival than placebo, and there were no fatalities brought on by the treatment.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form